Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Up 2.1 %

Cara Therapeutics stock opened at $4.85 on Friday. Cara Therapeutics has a 52 week low of $2.71 and a 52 week high of $10.44. The company’s 50 day moving average price is $5.05 and its two-hundred day moving average price is $4.33. The stock has a market cap of $22.18 million, a P/E ratio of -0.23 and a beta of 0.41.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new stake in shares of Cara Therapeutics during the 3rd quarter worth $29,000. FMR LLC increased its holdings in Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 32,789 shares during the last quarter. Curi RMB Capital LLC bought a new stake in Cara Therapeutics in the fourth quarter worth about $277,000. Shay Capital LLC bought a new stake in Cara Therapeutics in the fourth quarter worth about $524,000. Finally, Rockefeller Capital Management L.P. purchased a new position in Cara Therapeutics in the fourth quarter valued at about $953,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.